

## ABSTRACT for Restore Medical's Presentation

Questions for categories: **Medical Devices**

### Investment Rational

Contraband is a novel transcatheter pulmonary arterial band, which is implanted in the pulmonary arteries. Target population is HFrEF patients with preserved RV function. The US MKT size is 6M patients while the ContraBand can treat 25% of the entire MKT. Restore Medical is a clinical phase company and its FIH study for evaluating safety and early efficacy is in process.

### Business Strategy

Based on early feasibility data in EU and pivotal study in the US the company will gain PMA and CE MARK

#### ○ Core Technology

The ContraBand is implant delivered via 18F system into the PAs. It is the only HF device placed outside of the heart with the unique ability to reverse the therapy even long after the implantation. Contraband can be a standalone therapy for LV remodeling but can also work together with any other HF device

#### ○ Product Profile/Pipeline

Restore Medical develops the ContraBand for the treatment of LV-DCM, currently at early clinical phase with a total MKT potential of \$3.75B in the US alone. Next milestones: Finalizing FIH study in EU (Q4, 2022), IDE launch (Q1, 2024). The company collaborates with leading physicians and institutions across Europe.

#### ○ What's Next?

The company develop the next generation which will enhance its value proposition, enroll patients into a Feasibility study and submit a file to FDA. The company will finalize a B investment round by Q4, 2022